<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="7361"><DrugName>fibrinogen antagonists, Telios</DrugName><DrugSynonyms><Name><Value>fibrinogen antagonists, Telios</Value></Name></DrugSynonyms><CompanyOriginator id="22148">Telios Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="22148">Telios Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22148" type="Company"><TargetEntity id="5031364845" type="organizationId">Telios Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="745" type="ciIndication"><TargetEntity id="10061216" type="MEDDRA"></TargetEntity><TargetEntity id="D007238" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="325">Thromboembolism</Indication><Indication id="65">Stroke</Indication><Indication id="745">Infarction</Indication></IndicationsSecondary><ActionsPrimary><Action id="165">Factor I antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="312">Platelet aggregation inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra><Ephmra><Code>B2D5</Code><Name>Fibrinogen</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-04T04:32:26.000Z</LastModificationDate><ChangeDateLast>2002-04-09T11:15:07.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Telios was developing peptides selective for the IIb/IIIa integrin which inhibit the action of fibrinogen and decrease the formation of clots, as potential treatments for conditions such as myocardial infarction and stroke [&lt;ulink linkID="182504" linkType="reference"&gt;182504&lt;/ulink&gt;]. The company has stated, however, that these peptides are no longer undergoing discovery [&lt;ulink linkID="267269" linkType="reference"&gt;267269&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="325">Thromboembolism</Indication><Source id="267269" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><Source id="267269" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="745">Infarction</Indication><Source id="267269" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><Source id="182504" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="745">Infarction</Indication><Source id="182504" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22148">Telios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><Source id="155838" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00711"><Name>Factor I</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COc1ccc(cc1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)NCC(=O)NC(C(=O)N2)CC(=O)O)CCCNC(=N)N)C(=O)N)C(=O)CCNC(=N)N</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>